欢迎光临~北京凯森莱科技有限公司
语言选择: 中文版 ∷  英文版
  • 3080-30-6 , 1-O-乙酰-2,3,5-三-O-苯甲酰基-β-L-呋喃核糖, CAS:3080-30-6
3080-30-6 , 1-O-乙酰-2,3,5-三-O-苯甲酰基-β-L-呋喃核糖, CAS:3080-30-6

3080-30-6 , 1-O-乙酰-2,3,5-三-O-苯甲酰基-β-L-呋喃核糖, CAS:3080-30-6

3080-30-6 , 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-L-ribofuranose,
1-O-乙酰-2,3,5-三-O-苯甲酰基-β-L-呋喃核糖,
CAS:3080-30-6
C28H24O9 / 504.48
MFCD04114304

1-O-Acetyl-2,3,5-tri-O-benzoyl-b-L-ribofuranose

1-O-乙酰-2,3,5-三-氧-苯甲酰基-β-L-呋喃核糖,

1-O-Acetyl-2,3,5-tri-O-benzoyl-b-L-ribofuranose is a reactive proton that has been shown in kinetic studies to be able to react with chloride ions. It is a stereoselective molecule that can be used to produce xanthosine (X), guanosine (G), and 2-aminoadenosine (A) from the corresponding ribofuranosides. 1-O-Acetyl-2,3,5-tri-O-benzoyl ribofuranose has been shown to inhibit viral replication in the case of hepatitis B and C viruses. This compound also inhibits cross coupling reactions with anions such as chloride ions and can be used as a potential antiviral agent or drug candidate for treatment of chronic hepatitis C infections.

1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose is a natural nucleoside isolated from the plant Ginkgo biloba. It belongs to the group of ribonucleosides, which are nucleosides containing ribose as the sugar component. This compound is commonly referred to as Ginkgolide J, and it has shown promising biological activities, making it a subject of interest in the field of drug discovery.

Synthesis and Characterization:

The synthesis of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose is a multi-step process that involves the protection and deprotection of hydroxyl groups in ribose. One of the methods involves the benzoylation of ribose, followed by acetylation and then benzoylation of the remaining hydroxyl groups. The final product is purified using chromatography techniques. Characterization of the compound is done using various spectroscopic techniques, such as NMR, IR, and mass spectrometry.

Analytical Methods:

Analytical methods, such as HPLC and TLC, have been used for the quantification and identification of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose in various extraction methods from Ginkgo biloba plant extracts.

Biological Properties:

1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose has been shown to possess various biological activities, including anti-inflammatory, anti-tumor, and anti-oxidant activities. It also inhibits platelet-activating factor (PAF) and shows inhibition of the binding of PAF to its receptor. The compound has also shown to have neuroprotective activity, inhibiting the release of excitatory neurotransmitters and protecting neurons from oxidative stress.

Toxicity and Safety in Scientific Experiments:

Studies have shown that 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose has no acute toxicity in animal experiments. However, chronic toxicity studies have not been conducted.

Applications in Scientific Experiments:

1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose has been used in numerous studies investigating its biological activities, making it a subject of interest in drug discovery. It has been tested for its anti-tumor activity in vitro and in vivo, showing promising results. It has also been studied for its inhibitory effects on PAF, a mediator involved in various inflammatory and allergic diseases.

Current State of Research:

Research on 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose is ongoing, with a particular focus on its neuroprotective activity and its potential use as a therapeutic agent for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Its anti-tumor activity is also being investigated, particularly in the treatment of lung cancer.

Potential Implications in Various Fields of Research and Industry:

The potential implications of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose in various fields of research and industry are vast, particularly in drug discovery and development. Its neuroprotective and anti-tumor activities make it a subject of interest in the development of therapeutic agents for various diseases.

Limitations and Future Directions:

One limitation of research on 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose is the lack of chronic toxicity studies in animals. Future research should investigate the chronic toxicity of the compound and its long-term effects. Additionally, further research on its mechanism of action and potential therapeutic applications is needed, particularly in neurodegenerative diseases and cancer.

Future Directions:

- Investigating the potential use of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose as a therapeutic agent for other diseases, such as cardiovascular diseases and inflammatory diseases.

- Studying the combinatorial effects of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose with other compounds and drugs for improved efficacy.

- Developing new synthetic methods for the production of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose that are more efficient and environmentally friendly.

- Investigating the pharmacokinetics and pharmacodynamics of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose in humans, including its bioavailability and metabolism.

CAS Number3080-30-6
Product Name1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-L-ribofuranose
IUPAC Name[(2S,3S,4S,5R)-5-acetyloxy-3,4-dibenzoyloxyoxolan-2-yl]methyl benzoate
Molecular FormulaC28H24O9
Molecular Weight504.48 g/mol
InChIInChI=1S/C28H24O9/c1-18(29)34-28-24(37-27(32)21-15-9-4-10-16-21)23(36-26(31)20-13-7-3-8-14-20)22(35-28)17-33-25(30)19-11-5-2-6-12-19/h2-16,22-24,28H,17H2,1H3/t22-,23-,24-,28-/m0/s1
InChI KeyGCZABPLTDYVJMP-TVQWTUMOSA-N
SMILESCC(=O)OC1C(C(C(O1)COC(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3)OC(=O)C4=CC=CC=C4
Canonical SMILESCC(=O)OC1C(C(C(O1)COC(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3)OC(=O)C4=CC=CC=C4
Isomeric SMILESCC(=O)O[C@@H]1[C@H]([C@H]([C@@H](O1)COC(=O)C2=CC=CC=C2)OC(=O)C3=CC=CC=C3)OC(=O)C4=CC=CC=C4


CAS No: 3080-30-6 Synonyms: b-L-Ribofuranose 1-acetate 2,3,5-tribenzoate MDL No: MFCD04114304 Chemical Formula: C28H24O9 Molecular Weight: 504.48
References: 1. Sivets GG, Klennitskaya TV, Zhernosek EV, et al., Synthesis 2002, p2532. Chu CK, Ma T, Shanmuganathan K, et al., Antimicrob. Agents Chemother. 1995, 39, 4 p979

在线询价

用手机扫描二维码关闭
二维码